| Autor: |
Ravinet Trillou C; Central Nervous System Research, Sanofi-Synthélabo, 31036 Toulouse Cedex, France. christine.ravinet-trillou@sanofi-synthelabo.com, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie P |
| Jazyk: |
angličtina |
| Zdroj: |
American journal of physiology. Regulatory, integrative and comparative physiology [Am J Physiol Regul Integr Comp Physiol] 2003 Feb; Vol. 284 (2), pp. R345-53. Date of Electronic Publication: 2002 Oct 24. |
| DOI: |
10.1152/ajpregu.00545.2002 |
| Abstrakt: |
Because the CB1 receptor antagonist SR141716 was previously reported to modulate food intake in rodents, we studied its efficacy in reducing obesity in a diet-induced obesity (DIO) model widely used for research on the human obesity syndrome. During a 5-wk treatment, SR141716 (10 mg. kg(-1). day(-1) orally) induced a transient reduction of food intake (-48% on week 1) and a marked but sustained reduction of body weight (-20%) and adiposity (-50%) of DIO mice. Furthermore, SR141716 corrected the insulin resistance and lowered plasma leptin, insulin, and free fatty acid levels. Most of these effects were present, but less pronounced at 3 mg. kg(-1). day(-1). In addition to its hypophagic action, SR141716 may influence metabolic processes as the body weight loss of SR141716-treated mice was significantly higher during 24-h fasting compared with vehicle-treated animals, and when a 3-day treatment was compared with a pair feeding. SR141716 had no effect in CB1 receptor knockout mice, which confirmed the implication of CB1 receptors in the activity of the compound. These findings suggest that SR141716 has a potential as a novel anti-obesity treatment. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
